Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.66 |
| ▸ | F7 | P08709 | 4/20 | 0.66 |
| ▸ | F3 | P13726 | 4/20 | 0.66 |
| ▸ | PPARD | Q03181 | 4/20 | 0.66 |
| ▸ | PPARA | Q07869 | 4/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | ESR1 | P03372 | 1/20 | 0.66 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.66 |
| ▸ | CASP6 | P55212 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | FABP3 | P05413 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.64 |
| ▸ | FABP4 | P15090 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23950453 | 0.98 | ALDH1A1 (0.67) | PPARGF7F3PPARDPPARA | |
| SCHEMBL25834788 | 0.98 | ALDH1A1 (0.67) | PPARGF7F3PPARDPPARA | |
| SCHEMBL21448748 | 0.98 | ALDH1A1 (0.67) | PPARGF7F3PPARDPPARA | |
| SCHEMBL11892066 | 0.98 | ALDH1A1 (0.67) | PPARGF7F3PPARDPPARA | |
| SCHEMBL20074366 | 0.98 | ALDH1A1 (0.67) | PPARGF7F3PPARDPPARA | |
| SCHEMBL24005588 | 0.95 | PPARG (0.64) | PPARGF7F3PPARDPPARA | |
| SCHEMBL23950505 | 0.95 | ALDH1A1 (0.64) | PPARGF7F3PPARDPPARA | |
| SCHEMBL23950132 | 0.93 | TERT (0.63) | PPARGF7F3PPARDPPARA | |
| SCHEMBL23950153 | 0.93 | TERT (0.63) | PPARGF7F3PPARDPPARA | |
| SCHEMBL23950156 | 0.93 | TERT (0.63) | PPARGF7F3PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649215-B2 | Compositions and methods for the treatment of oral infectious diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2023-05-16 | — | — | US | disclosed |
| US-20220401467-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-12-22 | — | — | US | disclosed |
| US-11225463-B2 | Compositions and methods for the treatment of oral infectious diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2022-01-18 | — | — | US | disclosed |
| US-11013757-B2 | Oligonucleotides, compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2021-05-25 | — | — | US | disclosed |
| US-20200361874-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2020-11-19 | — | — | US | disclosed |
| US-10450568-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-10-22 | — | — | US | disclosed |
| US-20190209604-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649215-B2 | Compositions and methods for the treatment of oral infectious diseases | SI, HBG1, HBG2 | PPARG 1085/4885F7 4/4885F3 508/4885 |
| US-20190209604-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | TLR9, RNGTT, NT5C3B | PPARG 2903/4885F7 3960/4885F3 4589/4885 |
| US-20200361874-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | SI, HBG1, HBG2 | PPARG 1085/4885F7 4/4885F3 508/4885 |
| US-11225463-B2 | Compositions and methods for the treatment of oral infectious diseases | SI, HBG1, HBG2 | PPARG 1085/4885F7 4/4885F3 508/4885 |
| US-20220401467-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | TLR9, RNGTT, NT5C3B | PPARG 2903/4885F7 3960/4885F3 4589/4885 |
| US-11013757-B2 | Oligonucleotides, compositions and methods thereof | TLR9, RNGTT, NT5C3B | PPARG 2903/4885F7 3960/4885F3 4589/4885 |
| US-10450568-B2 | Oligonucleotide compositions and methods thereof | RBM17, HNRNPA2B1, HNRNPA1 | PPARG 2972/4885F7 4320/4885F3 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.